← Eichor
Study identifier: NCT06563388 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

Condition: Oligometastasis · Lung Cancer · Colo-rectal Cancer  ·  Sponsor: Roswell Park Cancer Institute

PhasePhase 3
Planned participants800
Who can joinAll sexes, 1 Year to no upper limit
Healthy volunteersNo

About this study

This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (Trial 1), colorectal (Trial 2), and prostate (Trial 3) cancers

This description comes directly from the study's public registry record.

Talk to the study team

ASK RPCI  ·  1-800-767-9355  ·  askroswellpark@roswellpark.org

Always discuss trial participation with your own doctor first.

Locations (1)

Roswell Park Comprehensive Cancer CenterBuffalo, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06563388